

Global Colorectal Cancer Drugs and Companies Pipeline Review H1 2017

Colorectal Cancer Therapeutics Development and Professional Review Analysis 2017

PUNE, INDIA, October 13, 2017 /EINPresswire.com/ -- Summary

This report provides an overview of the [colorectal cancer](#) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017> □

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates

and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents	4
1.1 List of Tables	5
1.2 List of Figures	10
2 Introduction	11
2.1 Colorectal Cancer Report Coverage	11
2.2 Anal Cancer - Overview	11
2.3 Rectal Cancer - Overview	11
2.4 Colorectal Cancer - Overview	11
3 Therapeutics Development	12
3.1 Anal Cancer	12
3.2 Rectal Cancer	16
3.3 Colorectal Cancer	18
4 Therapeutics Assessment	56
4.1 Anal Cancer	56
4.2 Rectal Cancer	63
4.3 Colorectal Cancer	71
5 Companies Involved in Therapeutics Development	100
5.1 Anal Cancer	100
5.2 Rectal Cancer	108
5.3 Colorectal Cancer	114
6 Dormant Projects	241
6.1 Anal Cancer	241
6.2 Rectal Cancer	241
6.3 Colorectal Cancer	242
7 Discontinued Products	261
7.1 Anal Cancer	261
7.2 Colorectal Cancer	261
8 Product Development Milestones	265
8.1 Anal Cancer	265
8.2 Rectal Cancer	278
8.3 Colorectal Cancer	280
...Continued	□

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact

the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.